Lomecel-B Injection in Patients With Hypoplastic Left Heart Syndrome: A Phase I/II Study (ELPIS)
Latest Information Update: 31 Oct 2024
At a glance
- Drugs Laromestrocel (Primary)
- Indications Hypoplastic left heart syndrome
- Focus Adverse reactions
- Acronyms ELPIS; ELPIS I
- Sponsors Longeveron
Most Recent Events
- 27 Oct 2024 According to a Longeveron media release, data from this study were presented at the Congenital Heart Surgeons Society (CHSS) 51st Annual Meeting taking place October 27-28, 2024 in Chicago, Illinois.
- 27 Oct 2024 Results presented in a Longeveron Media Release.
- 09 Oct 2024 According to a Longeveron media release, Based on the strength of the ELPIS I data company is conducting the ELPIS II Phase 2b clinical trial, which is evaluating cellular therapy Lomecel-B as a potential adjunct therapy for treating HLHS, and which, if positive, may serve as the foundation for a BLA submission for potential approval of Lomecel-B.